The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.
BET
Microglia/macrophage
Neuroinflammation
PROTAC
Retinal degeneration
cGAS-STING
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
received:
15
01
2023
accepted:
11
05
2023
medline:
24
5
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Chronic inflammation significantly contributes to photoreceptor death in blinding retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that act as key proinflammatory factors. We recently found the first-generation BET inhibitor JQ1 alleviated sodium iodate-induced retinal degeneration by suppressing cGAS-STING innate immunity. Here, we investigated the effects and mechanism of dBET6, a proteolysis‑targeting chimera (PROTAC) small molecule that selectively degrades BET by the ubiquitin‒proteasome system, in light-induced retinal degeneration. Mice were exposed to bright light to induce retinal degeneration, and the activation of cGAS-STING was determined by RNA-sequencing and molecular biology. Retinal function, morphology, photoreceptor viability and retinal inflammation were examined in the presence and absence of dBET6 treatment. Intraperitoneal injection of dBET6 led to the rapid degradation of BET protein in the retina without detectable toxicity. dBET6 improved retinal responsiveness and visual acuity after light damage (LD). dBET6 also repressed LD-induced retinal macrophages/microglia activation, Müller cell gliosis, photoreceptor death and retinal degeneration. Analysis of single-cell RNA-sequencing results revealed cGAS-STING components were expressed in retinal microglia. LD led to dramatic activation of the cGAS-STING pathway, whereas dBET6 suppressed LD-induced STING expression in reactive macrophages/microglia and the related inflammatory response. This study indicates targeted degradation of BET by dBET6 exerts neuroprotective effects by inhibiting cGAS-STING in reactive retinal macrophages/microglia, and is expected to become a new strategy for treatment of retinal degeneration.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic inflammation significantly contributes to photoreceptor death in blinding retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that act as key proinflammatory factors. We recently found the first-generation BET inhibitor JQ1 alleviated sodium iodate-induced retinal degeneration by suppressing cGAS-STING innate immunity. Here, we investigated the effects and mechanism of dBET6, a proteolysis‑targeting chimera (PROTAC) small molecule that selectively degrades BET by the ubiquitin‒proteasome system, in light-induced retinal degeneration.
METHODS
METHODS
Mice were exposed to bright light to induce retinal degeneration, and the activation of cGAS-STING was determined by RNA-sequencing and molecular biology. Retinal function, morphology, photoreceptor viability and retinal inflammation were examined in the presence and absence of dBET6 treatment.
RESULTS
RESULTS
Intraperitoneal injection of dBET6 led to the rapid degradation of BET protein in the retina without detectable toxicity. dBET6 improved retinal responsiveness and visual acuity after light damage (LD). dBET6 also repressed LD-induced retinal macrophages/microglia activation, Müller cell gliosis, photoreceptor death and retinal degeneration. Analysis of single-cell RNA-sequencing results revealed cGAS-STING components were expressed in retinal microglia. LD led to dramatic activation of the cGAS-STING pathway, whereas dBET6 suppressed LD-induced STING expression in reactive macrophages/microglia and the related inflammatory response.
CONCLUSIONS
CONCLUSIONS
This study indicates targeted degradation of BET by dBET6 exerts neuroprotective effects by inhibiting cGAS-STING in reactive retinal macrophages/microglia, and is expected to become a new strategy for treatment of retinal degeneration.
Identifiants
pubmed: 37217935
doi: 10.1186/s12974-023-02804-y
pii: 10.1186/s12974-023-02804-y
pmc: PMC10201800
doi:
Substances chimiques
dBET6
0
Nucleotidyltransferases
EC 2.7.7.-
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Subventions
Organisme : National Natural Science Foundation of China
ID : 81970787
Organisme : National Natural Science Foundation of China
ID : 82271071
Organisme : National Natural Science Foundation of China
ID : 82070969
Organisme : Guangzhou Municipal University Joint Funding Project
ID : SL2023A03J00488
Informations de copyright
© 2023. The Author(s).
Références
Science. 2020 Nov 20;370(6519):
pubmed: 33004674
J Vis Exp. 2018 Jun 5;(136):
pubmed: 29939190
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6264-E6273
pubmed: 29915052
Front Cell Neurosci. 2020 Aug 06;14:198
pubmed: 32848611
Gene Expr Patterns. 2004 Sep;4(5):513-9
pubmed: 15261828
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
J Clin Immunol. 2021 Apr;41(3):501-514
pubmed: 33532887
Nat Commun. 2021 Apr 19;12(1):2327
pubmed: 33875663
Prog Retin Eye Res. 2005 Mar;24(2):275-306
pubmed: 15610977
Cold Spring Harb Perspect Biol. 2014 Jul 01;6(7):a018762
pubmed: 24984779
Cell Death Dis. 2019 Oct 25;10(11):815
pubmed: 31653826
EMBO Mol Med. 2015 Jul 02;7(9):1179-97
pubmed: 26139610
J Neuroinflammation. 2017 Jan 19;14(1):14
pubmed: 28103888
Free Radic Biol Med. 2022 Jan;178:147-160
pubmed: 34875339
Nat Rev Immunol. 2021 Sep;21(9):548-569
pubmed: 33833439
Mol Cell. 2017 Jul 6;67(1):5-18.e19
pubmed: 28673542
J Neuroinflammation. 2015 Nov 17;12:209
pubmed: 26576678
Bioorg Med Chem. 2022 Nov 1;73:117033
pubmed: 36202064
J Neurosci. 2017 Mar 22;37(12):3294-3310
pubmed: 28235894
Immunity. 2019 Mar 19;50(3):723-737.e7
pubmed: 30850344
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
J Immunol. 2013 Apr 1;190(7):3670-8
pubmed: 23420887
J Neuroinflammation. 2022 Jun 27;19(1):168
pubmed: 35761277
Nucleic Acids Res. 2019 Jan 8;47(D1):D721-D728
pubmed: 30289549
Neurochem Int. 2019 Jul;127:94-102
pubmed: 30872008
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Cell Death Differ. 2022 Sep;29(9):1816-1833
pubmed: 35347235
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Nat Commun. 2021 Nov 15;12(1):6565
pubmed: 34782623
J Neuroinflammation. 2016 Feb 24;13:47
pubmed: 26911327
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Science. 2013 Feb 15;339(6121):826-30
pubmed: 23258412
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2118819119
pubmed: 35394877
Nat Rev Drug Discov. 2019 Aug;18(8):609-628
pubmed: 31273347
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217
Front Mol Biosci. 2021 Sep 16;8:748449
pubmed: 34604312
Cell Death Dis. 2020 Sep 25;11(9):805
pubmed: 32978368
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
JAMA Ophthalmol. 2020 Oct 1;138(10):1026-1034
pubmed: 32789526
Proc Natl Acad Sci U S A. 2022 Nov 29;119(48):e2208934119
pubmed: 36409895
J Cell Biol. 1983 Jul;97(1):253-7
pubmed: 6345555
Cell Rep. 2021 Nov 2;37(5):109955
pubmed: 34731634
Nat Commun. 2019 Oct 25;10(1):4902
pubmed: 31653841
Nat Rev Genet. 2010 Apr;11(4):273-84
pubmed: 20212494
Nat Med. 2018 Jan;24(1):50-61
pubmed: 29176737